PMVP
PMV Pharmaceuticals Inc

474
Loading...
Loading...
News
all
press releases
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; PMV Pharma) today announced a partnership to develop Foundation Medicines tissue-based comprehensive genomic profiling test...
Business Wire·1y ago
News Placeholder
More News
News Placeholder
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2...
Globe Newswire·1y ago
News Placeholder
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation...
Globe Newswire·1y ago
News Placeholder
PEAK6 Investments LLC Invests $200,000 in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)
PEAK6 Investments LLC purchased a new position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP Free Report) during the third quarter, Holdings Channel.com reports. The fund purchased...
Zolmax·2y ago
News Placeholder
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. increased its position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP Free Report) by 3.5% during the third quarter, according to the...
Zolmax·2y ago
News Placeholder
PMV Pharmaceuticals reports FY results
PMV Pharmaceuticals reports FY results...
SeekingAlpha.com: All News·2y ago
News Placeholder
PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results
Strategic Focus on Rezatapopt Advances as Company Extends Cash RunwayRelated Stocks: PMVP...
GuruFocus·2y ago
News Placeholder
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors...
Globe Newswire·2y ago
News Placeholder
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
Globe Newswire·2y ago
News Placeholder
Principal Financial Group Inc. Decreases Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)
Principal Financial Group Inc. lowered its position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP Free Report) by 0.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor...
Zolmax·2y ago

Latest PMVP News

View

Advertisement. Remove ads.

Advertisement. Remove ads.